The aim of this study is to investigate how many leiomyoma patients are exposed to bisphenol-A (BPA) , an endocrine disruptor, and whether the serum concentration of BPA is related to leiomyoma growth. Initially, 128 patients were divided into one control and three leiomyoma groups (mild, moderate and severe) according to the size of the leiomyomas. Serum BPA concentrations were measured by liquid chromatography and mass spectrometry (LC/MS) . Nearly two-thirds of leiomyoma patients were exposed to BPA and the range of BPA was from non-detection to 2.603 ng/ml. The mean BPA concentrations in the groups were 1.015 ± 0.775 ng/ml (control) , 0.774 ± 0.834 ng/ml (mild) , 1.261 ± 0.797 ng/ml (moderate) and 1.244 ± 0.860 ng/ml (severe) (p = 0.158) . After recombination into two group, Group 1 (control plus mild) vs. Group 2 (moderate plus severe) , higher level was found in Group 2 even with no statistical significance (p = 0.06) . In conclusion, about two-thirds of leiomyoma patients were exposed to BPA, but it may not have growth promoting effect on leiomyoma.
In patients with immature teratoma of the ovary, blood-borne metastasis to organ parenchyma, such as the lungs, liver, or brain, are uncommon. Moreover, soft tissue metastasis is extremely rare. We describe a 31-year-old woman with an immature teratoma of the left ovary, which metastasized to soft tissue of the right thigh after surgery. Because of the rarity of this condition, we report the results of treatment and review the literature.
Objective: To investigate how many leiomyoma patients are exposed to bisphenol-A (BPA) and whether the serum concentration of BPA is related to leiomyoma growth. Methods: Total 131 patients were recruited for measuring BPA. Initially, leiomyoma patients were divided into three groups, mild (n=38), moderate (n=33), and severe (n=30) according to the size of the leiomyomas. The control (n=30) group was defined as having no leiomyomas. The identification and diameter measurements of leiomyomas was performed by transvaginal ultrasonography. Serum BPA concentrations were measured by enzyme linked immunosorbent assay. Results: BPA was detected in 83.9% out of 131 samples totally, and 83.1% out of 101 leiomyoma patients. In detail, the detection rates of serum BPA were 86.7% in control group, 71.1% in mild group, 84.9% in moderate group, and 96.7% in severe group. The mean BPA concentrations in the control group was 0.557±0.086 ng/mL and those in the leiomyoma groups were 0.273±0.052 ng/mL (mild), 0.336±0.063 ng/mL (moderate), and 0.636±0.075 ng/mL (severe) (P=0.0003). Values are mean±standard error. Conclusions:The detection rate of serum BPA in control and leiomyoma groups were 86.7% and 83.1% respectively. However, there was no statistical significance of serum BPA concentrations between control and leiomyoma groups. To verify the effect of BPA on the leiomyoma growth, close and sequential monitoring for the person who have exposure risk is recommended.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.